Allergan Performs Better Than Expected, But Still Conducting Strategic Review
Executive Summary
Financials are holding up well despite generics launching against multiple Allergan products, but with stock price falling the company is conducting a strategic review to make sure it isn't missing out on any alternative business strategies that could boost the enterprise's value.
You may also be interested in...
Activist Investors Seek Action At Allergan, But Are They Aligned?
Investors want to separate the CEO and chairman roles held by Brent Saunders, among other demands, but it's unclear whether new investor Carl Icahn – a prior Saunders supporter – will pursue the same causes.
US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs
Pre-ANDA meeting requests were high in some product categories where FDA conducted research projects, suggesting agency may influence sponsors' development priorities.
US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs
Pre-ANDA meeting requests were high in some product categories where FDA conducted research projects, suggesting agency may influence sponsors' development priorities.